3-thienylmethyl isocyanate | 114546-13-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 杂芳族化合物
• 英文名称: 3-thienylmethyl isocyanate
• 英文别名: thiophen-3-ylmethyl isocyanate；(thien-3-yl)methyl isocyanate；3-(Isocyanatomethyl)thiophene
• CAS: 114546-13-3
• 化学式: C₆H₅NOS
• mdl: MFCD18301257
• 分子量: 139.178
• InChiKey: JOOMUQIUCLRJPG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  9
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.166
• 拓扑面积：
  57.7
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-thienylmethyl isocyanate 在 4-二甲氨基吡啶 、 苯甲醚 、 三乙胺 、 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 反应 3.0h， 生成 4-{3,3-Diethyl-4-oxo-1-[(thiophen-3-ylmethyl)-carbamoyl]-azetidin-2-yloxy}-benzoic acid
  参考文献：
  名称：

  Orally active .beta.-lactam inhibitors of human leukocyte elastase-1. Activity of 3,3-diethyl-2-azetidinones

  摘要：

  A thorough analysis of the mechanism of inhibition of human leukocyte elastase (HLE) by a monocyclic beta-lactam and the mechanism of beta-lactam hydrolysis led to the preparation of potent and highly stable inhibitors of HLE. This work led to the identification of 4-[(4-carboxyphenyl)-oxy]-3,3-diethyl-1-[[(phenylmethyl)amino]carbonyl]-2-azetidinone (2) as the first orally active inhibitor of human leukocyte elastase (HLE). Analogs of 2 with different substituents on the urea N were synthesized and evaluated for their activity in vitro against HLE as well as in vivo in a hamster lung hemorrhage model. Compounds with a methyl or a methoxy group in the para position of the benzene ring were very potent in both assays. The results are discussed on the basis of the proposed model for the binding of this class of inhibitors to HLE and a possible mechanism of inhibition is presented.

  DOI：

  10.1021/jm00099a003
• 作为产物：
  描述：

  3-噻吩乙酸 在 二苯基膦叠氮化物 、 三乙胺 作用下， 以 乙腈 为溶剂， 反应 2.0h， 以73%的产率得到3-thienylmethyl isocyanate
  参考文献：
  名称：

  双环扩大法合成Aza-1,2-噻吩金属

  摘要：

  使用两个环扩大反应将脂环族8元2-氧代环辛烷-1-羧酸烯丙基酯（11）转变为13元10-氮杂-[11]-（2,3）-噻吩基-1,9-二酮（17）。第一步得到大环酰亚胺烯丙基N-（3-噻吩甲基）-2,10-二氧-1-氮杂环癸烷-3-羧酸酯（15），脱保护后得到N-（3-噻吩甲基）-1-氮杂环癸烷-2 ，10-二酮（16）。在第二步骤中，通过使用LDA将N-噻吩基取代基掺入大环中。总产率为45％。该方法还用于转化12-元烯丙基2-氧代环十二烷-1-羧酸酯（20）到17元14-氮杂-[15]-（2,3）-噻吩基-1,13-二酮（23）中。

  DOI：

  10.1016/s0040-4020(00)00651-7

文献信息

• Synthesis and growth-inhibitory activities of imidazo[5,1-<i>d</i>]-1,2,3,5-tetrazine-8-carboxamides related to the anti-tumour drug temozolomide, with appended silicon, benzyl and heteromethyl groups at the 3-position
  作者：David Cousin、Marc G. Hummersone、Tracey D. Bradshaw、Jihong Zhang、Christopher J. Moody、Magdalena B. Foreiter、Helen S. Summers、William Lewis、Richard T. Wheelhouse、Malcolm F. G. Stevens

  DOI：10.1039/c7md00554g

  日期：——

  The synthesis and biological evaluation of imidazotetrazines substituted at N-3 is described.

  对N-3位取代的咪唑四氮唑类化合物的合成和生物评价进行了描述。
• [EN] INHIBITORS OF INTEGRIN ALPHA 2 BETA 1 AND METHODS OF USE<br/>[FR] INHIBITEURS DE L'INTÉGRINE ALPHA 2 BÊTA 1 ET PROCÉDÉS D'UTILISATION
  申请人：UNIV CALIFORNIA

  公开号：WO2019178248A1

  公开（公告）日：2019-09-19

  Disclosed herein, inter alia, are inhibitors of integrin alpha 2 beta 1 and methods of using the same.

  本文披露了抑制整合素α2β1的方法，以及使用这些方法的方法。
• 3-Substituted-4-Oxo-3,4-Dihydro-Imidazo[5,1-d][1,2,3,5-Tetrazine-8-Carboxylic Acid Amides and Their Use
  申请人：Stevens Malcolm Francis Graham

  公开号：US20100286088A1

  公开（公告）日：2010-11-11

  The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain 3-substituted-4-oxo-3,4-dihydro-imidazo[5,1-d][1,2,3,5]tetrazine-8-carboxylic acid amide (collectively referred to herein as 3TM compounds). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit cell proliferation, and in the treatment of proliferative disorders such as cancer, etc., and methods of preparing such compounds.

  本发明涉及治疗化合物领域，更具体地涉及某些3-取代-4-氧代-3,4-二氢咪唑[5,1-d][1,2,3,5]四嗪-8-羧酸酰胺（统称为3TM化合物）。本发明还涉及包含这种化合物的制药组合物，以及在体内外使用这种化合物和组合物来抑制细胞增殖，在治疗增生性疾病如癌症等方面的应用，以及制备这种化合物的方法。
• 3-substituted-4-oxo-3,4-dihydro-imidazo[5,1-d][1,2,3,5-tetrazine-8-carboxylic acid amides and their use
  申请人：Stevens Malcolm Francis Graham

  公开号：US08450479B2

  公开（公告）日：2013-05-28

  The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain 3-substituted-4-oxo-3,4-dihydro-imidazo[5,1-d][1,2,3,5]tetrazine-8-carboxylic acid amide (collectively referred to herein as 3TM compounds). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit cell proliferation, and in the treatment of proliferative disorders such as cancer, etc., and methods of preparing such compounds.

  本发明涉及治疗化合物领域，更具体地涉及某些3-取代-4-氧代-3,4-二氢咪唑[5,1-d][1,2,3,5]四嗪-8-羧酸酰胺（统称为3TM化合物）。本发明还涉及包含这种化合物的制药组合物，以及在体内外使用这种化合物和组合物来抑制细胞增殖，治疗增殖性疾病如癌症等，以及制备这种化合物的方法。
• 3-Substituted-4-Oxo-3,4-Dihydro-Imidazo[5,1-d]1,2,3,5-Tetrazine-8-Carboxylic Acid Amides and Their Use
  申请人：Pharminox Limited

  公开号：US20130338104A1

  公开（公告）日：2013-12-19

  The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain 3-substituted-4-oxo-3,4-dihydro-imidazo[5,1-d][1,2,3,5]tetrazine-8-carboxylic acid amide (collectively referred to herein as 3TM compounds). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit cell proliferation, and in the treatment of proliferative disorders such as cancer, etc., and methods of preparing such compounds.

  本发明涉及治疗化合物领域，更具体地涉及某些3-取代-4-氧代-3,4-二氢咪唑[5,1-d][1,2,3,5]四唑-8-羧酸酰胺（以下统称为3TM化合物）。本发明还涉及包含这种化合物的制药组合物，以及在体内外使用这种化合物和组合物来抑制细胞增殖，治疗增生性疾病如癌症等的用途，以及制备这种化合物的方法。